Anti-Amyloid Imaging Abnormality in the Era of Anti-Amyloid Beta Monoclonal Antibodies: Recent Updates for the Radiologist
Lecanemab and donanemab have received full U.S. Food and Drug Administration (FDA) approval, and subsequently, lecanemab has been approved by the Korean FDA and it has recently entered commercial use in Korea. This has increased interest in anti-amyloid immunotherapy for Alzheimer’s disease. Anti...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
The Korean Society of Radiology
2025-01-01
|
| Series: | Journal of the Korean Society of Radiology |
| Subjects: | |
| Online Access: | https://doi.org/10.3348/jksr.2024.0140 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Lecanemab and donanemab have received full U.S. Food and Drug Administration (FDA) approval,
and subsequently, lecanemab has been approved by the Korean FDA and it has recently
entered commercial use in Korea. This has increased interest in anti-amyloid immunotherapy
for Alzheimer’s disease. Anti-amyloid immunotherapy has shown potential to
modify the progression of the disease by specifically binding to amyloid β, a key pathological
product in Alzheimer’s disease, and eliminating accumulated amyloid plaques in the
brain. However, this treatment can be accompanied by a side-effect, amyloid-related imaging
abnormalities (ARIA), which requires periodic monitoring by MRI. It is crucial to detect
ARIA and accurately assess the severity by radiology. The role of the radiologist is important
in this context, requiring proficiency in basic knowledge of ARIA, and in diagnosing/evaluating
ARIA. This review aims to comprehensively cover aspects of ARIA, including its definition,
pathophysiology, incidence, risk factors, assessment of severity by radiology, differential diagnosis,
and management. |
|---|---|
| ISSN: | 2951-0805 |